(Q28346358)

3 July 2017

Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4. (English)

1 reference

3 July 2017

0 references

Glazer NB

1

1 reference

PubMed ID

11159615

3 July 2017

Cheatham WW

series ordinal

2

1 reference

PubMed ID

11159615

3 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

3 July 2017

1 reference

3 July 2017

322

1 reference

3 July 2017

7280

1 reference

3 July 2017

235-236

1 reference

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction

3 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119484

Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119484

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119484

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119484

27 November 2018

Identifiers

DOI

10.1136/BMJ.322.7280.235

1 reference

3 July 2017

0 references

1 reference

PubMed ID

11159615